上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (6): 809-.doi: 10.3969/j.issn.1674-8115.2011.06.028

• 论著（临床研究） • 上一篇    下一篇

特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估

沈 俭1, 陈建华2, 俞奇伟1, 沈 杰1, 孙 鹏1   

  1. 上海交通大学 医学院附属新华医院 1.崇明分院泌尿外科, 上海 202150, 2.泌尿外科, 上海 200092
  • 出版日期:2011-06-28 发布日期:2011-06-27
  • 通讯作者: 陈建华, 电子信箱: hikaru_csa@hotmail.com。
  • 作者简介:沈 俭（1971—）, 男, 主治医师, 学士；电子信箱: sj18964758501@163.com。

Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia

SHEN Jian1, CHEN Jian-hua2, YU Qi-wei1, SHEN Jie1, SUN Peng1   

  1. 1.Department of Urology, Xinhua Hospital Chongming Branch, Shanghai Jiaotong University School of Medicine, Shanghai 202150, China；2.Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China
  • Online:2011-06-28 Published:2011-06-27

PDF (PC)

1427

摘要：

目的 评价特拉唑嗪与托特罗定联合应用治疗良性前列腺增生的疗效。方法 选择未经治疗的无严重梗阻症状的良性前列腺增生患者74例，随机分为特拉唑嗪组（单独使用特拉唑嗪，n=31）和联合用药组（特拉唑嗪+托特罗定，n=43），两组分别在治疗前后测定国际前列腺症状评分、储尿期刺激症状评分、最大尿流率、24 h平均尿量、残余尿量、24 h排尿次数、24 h尿失禁次数和夜尿次数，并记录出现的不良事件。结果 用药12周后，特拉唑嗪组国际前列腺症状评分、储尿期刺激症状评分、残余尿量、24 h排尿次数、尿失禁次数及夜尿均次较治疗前均明显下降（P＜0.05）；最大尿流率和平均尿量较治疗前均明显上升（P＜0.05）；治疗后，联合用药组国际前列腺症状评分、储尿期刺激症状评分、尿失禁次数和夜尿次数与特拉唑嗪组相比均有明显改善,差异有统计学意义（P＜0.05）。结论 特拉唑嗪与托特罗定联合应用于无严重梗阻症状的良性前列腺增生患者，可以更全面地缓解症状，改善患者的生活质量。

关键词: 良性前列腺增生, 特拉唑嗪, 托特罗定

Abstract:

Objective To evaluate the effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia. Methods Seventy-four patients with benign prostatic hyperplasia without serious obstructive symptom were randomly assigned to terazosin group (treated with terazosin only, n=31) and combined therapy group (treated with terazosin and tolterodine, n=43). The International Prostate Symptoms Score (IPSS), score on the urinary storage phase symptoms, maximum urinary flow rate, mean voiding volume per 24 h, residual urine volume, number of micturation per 24 h, number of incontinence per 24 h and number of enuresis nocturna were obtained before and after treatment, and the adverse events were recorded. Results Twelve weeks after treatment, the IPSS, score on the urinary storage phase symptoms, residual urine volume, number of micturation per 24 h, number of incontinence per 24 h and number of enuresis nocturna significantly decreased in terazosin group （P＜0.05）, while maximum urinary flow rate and mean voiding volume significantly increased (P＜0.05）. There were significant differences in IPSS, score on the urinary storage phase symptoms, number of incontinence and number of enuresis nocturna between two groups after treatment （P＜0.05）. Conclusion Combined therapy with terazosin and tolterodine can well relieve the symptoms of benign prostatic hyperplasia without serious obstruction of urinary tract.

Key words: benign prostatic hyperplasia, terazosin, tolterodine